Sorin Group Enrolling Patients in TRIUMPH-CRT European Clinical Trial
The Italy-based Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.
The 216-patient study will be conducted using Sorin Group’s Paradym CRT-D Tri-V device. It is designed to investigate the benefits of individually optimized Tri-V pacing over standard biventricular pacing in patients with a non-Left Bundle Branch Block morphology.
With a special connector that enables the use of three ventricular leads without the need for any separate adaptor, the Paradym CRT-D Tri-V paces the ventricles at three different locations. Standard CRT-D devices only deliver ventricular pacing at two different sites.
Sorin Group is a global medical device company and that focuses on the treatment of cardiovascular diseases. — Michael Cipriano